Guess which ASX All Ords stock is jumping 9% on $1.6b market opportunity

This small cap is having a big day. But why?

| More on:
A young man wearing a black and white striped t-shirt looks surprised.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

sdf

Orthocell Ltd (ASX: OCC) shares are catching the eye on Friday.

In morning trade, the ASX All Ords stock is up 9% to $1.32.

Why is this ASX All Ords stock jumping?

The catalyst for today's strong gain has been the release of a very promising announcement from the regenerative medicine company this morning.

According to the release, the company has achieved a critical milestone in the commercialisation of its Remplir product in the US$1.6 billion US market.

Remplir is a collagen wrap used in nerve repair surgery to improve regeneration of damaged nerves and patient outcomes. The ASX All Ords stock notes that it is supported by robust clinical evidence. This includes recent studies confirming its superiority over standard suture techniques in nerve regeneration, earlier return to function, and higher quality nerve tissue restoration.

What was announced?

This morning, Orthocell revealed that the first successful surgery using the flagship nerve repair product has been completed in the United States.

The procedure was performed overnight at a hospital in Ohio and used Remplir in a surgical procedure to repair a foot nerve injury. The surgery was conducted using product manufactured at Orthocell's facility in Perth, Western Australia.

Management notes that the first use of Remplir in the US follows the product's US FDA 510(k) clearance in April and the subsequent appointment of 14 specialist distributors to drive adoption across key regions.

The ASX All Ords stock's CEO and managing director, Paul Anderson, said:

This first US surgery is a significant milestone for Orthocell and for the roll out of Remplir in the US. It signals the start of our commercial journey in the world's largest healthcare and nerve repair markets, and reflects our commitment to delivering innovative, clinically proven solutions to surgeons and their patients.

A critical first step in the US starts with getting Remplir into surgeons' hands for them to gain familiarity with its key features and benefits in clinical practice. These early cases play an important broader strategic role in building experience and knowledge amongst the surgical community.

The good news is that Anderson appears to believe that this could be the first of many surgeries using Remplir. He adds:

We are confident our efforts in the US are on track to drive material growth in sales of Remplir during the second half of calendar 2025.

Following today's strong gain, the Orthocell share price is now up approximately 250% since this time last year.

To put this into context, this means that a $1,000 investment a year ago would now be worth approximately $3,500.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has recommended Orthocell. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Three scientists wearing white coats and blue gloves dance together in a lab.
Share Market News

Is it too late to buy Pro Medicus shares?

Pro Medicus shares have risen 550% over 3 years. Have you missed the boat? Three experts weigh in.

Read more »

Researchers and doctors with futuristic 3d hologram overlay for body anatomy or dna in hospital clinic.
Healthcare Shares

These 5 ASX 200 healthcare shares gained the most weight in FY25

These stocks were in great health last financial year.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Guess which ASX 300 healthcare stock is charging higher on product launch news

Investors have responded positively to this announcement.

Read more »

Three healthcare workers look and point at at medical image
Share Market News

Pro Medicus shares surge 10% to crack $300 as healthcare leads ASX 200 sectors

Pro Medicus shares just keep on going, rising 625% over the past three years.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Here are the latest growth forecasts for the CSL share price

Can this biotech giant deliver healthy returns?

Read more »

Three scientists wearing white coats and blue gloves dance together in a lab.
Healthcare Shares

UP 127% in a year, why is the Pro Medicus share price rocketing higher again today?

ASX investors are sending Pro Medicus shares flying higher on Thursday. But why?

Read more »

Broker looking at the share price on her laptop with green and red points in the background.
Healthcare Shares

These healthcare stocks could be set to double according to broker

Interested in gaining exposure to the healthcare sector? These options could be ones to watch. 

Read more »

Shot of two young scientists using a laptop in a laboratory.
Healthcare Shares

Up 250% in a year, how much higher can this ASX healthcare share climb?  

The future looks promising for this biotech firm after delivering a record-quarterly result.

Read more »